Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for infusion - 240mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for injection - 350mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for infusion - 320mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for injection - 320mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - meglumine iotalamate - solution for infusion - 280mg/1ml

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - barium sulfate - enema

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

mallinckrodt uk commercial ltd - ioversol - solution for infusion - 320mg/1ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

st. mary's medical park pharmacy - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam capsules usp are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules usp should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. benzodiazepines may cause fetal harm when administered to a pregnant woman. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. reproduction studies in animals with temazepam were performed in rats and rabbits. in a perinatal-postnatal study in rats, oral doses of 60 mg/kg/da

Singapur - inglise - HSA (Health Sciences Authority)

covidien private limited - anaesthesiology - the hi-lo™ evac tracheal tube is indicated for airway management by oral intubation of the tracheal particularly in cases where duration of intubation is expected to be more than 24 hours or may not be predictable. where profuse secretions build up above the cuff or tracheal infection needs to be minimized, the evac lumen is indicated.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

mallinckrodt hospital products inc. - terlipressin (unii: 7z5x49w53p) (terlipressin - unii:7z5x49w53p) - terlivaz is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. limitation of use patients with a serum creatinine > 5 mg/dl are unlikely to experience benefit. terlivaz is contraindicated in patients experiencing hypoxia or worsening respiratory symptoms. terlivaz is contraindicated in patients with ongoing coronary, peripheral or mesenteric ischemia. risk summary based on findings from the published literature and on its mechanism of action, terlivaz may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . in small, published studies, administration of a single intravenous dose of terlipressin to pregnant women during the first trimester induced uterine contractions and endometrial ischemia. the limited published data are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. if terlivaz is used during pregnancy, the patient should be informed of the potential risk to the fetus. the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data in published reproductive toxicity animal studies, administration of terlipressin to pregnant guinea pigs at doses lower than the maximum recommended human dose of 4 mg/day caused a marked decrease in blood flow to the uterus and placenta. in rabbits, terlipressin is both embryotoxic and teratogenic (increased resorptions, increased implantation loss, fetal anomalies and fetal deformities). risk summary there are no data on the presence of terlipressin in human or animal milk, the effects on the breastfed infant, or the effect on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for terlivaz and any potential adverse effects on the breastfed child from terlivaz or from the underlying maternal condition. safety and effectiveness of terlivaz have not been established in pediatric patients. of the total number of patients in clinical studies treated with terlivaz, 55 (16%) were ≥65 years of age. no overall differences in safety or effectiveness were observed between these subjects and younger subjects; other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no dose adjustment is required in patients with hepatic impairment [see clinical pharmacology (12.3)] .